Program
Alpelisib
Also written as “BYL719”, “alpelisib” and “BYL719 as film-coated (FC) whole tablets”.
Its studies are mostly in Breast Neoplasms · Squamous Cell Carcinoma of Head and Neck · Neoplasms · Ovarian Neoplasms · Lymphatic Abnormalities, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 3310 open or running | phase 4since Nov 21, 2022 | Oct 6, 2010 | Jan 28, 2027phase 3 · NCT05038735 |
| Pfizer | 20 open or running | phase 2since Oct 30, 2012 | Oct 6, 2011 | none ahead |
| Criterium | 11 open or running | phase 2since Dec 27, 2021 | Dec 27, 2021 | none ahead |
| Kura Oncology | 10 open or running | phase 2since Jul 27, 2021 | Jul 27, 2021 | none ahead |
Also a collaborator on its studies: ImmunityBio.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 24 studies since Oct 6, 2010.
- Aug 19, 2020Phase 2 study in Advanced Breast CancerNovartis · NCT04524000 · 24 enrolled · Japan
- Sep 3, 2020Phase 2 study in Breast NeoplasmsNovartis · NCT04544189 · 69 enrolled · China
- Oct 14, 2020Phase 2 study in PIK3CA-related Overgrowth Spectrum (PROS)Novartis · NCT04589650 · 236 enrolled · United States, Canada, China and more
- Jan 25, 2021Phase 3 study in Ovarian NeoplasmsNovartis · NCT04729387 · 358 enrolled · United States, Argentina, Australia and more
- Apr 21, 2021Phase 2 study in Advanced Breast CancerNovartis · NCT04862143 · 2 enrolled · Sweden
- Jul 19, 2021Phase 2 study in PIK3CA-related Overgrowth Spectrum (PROS)Novartis · NCT04980833 · 41 enrolled · United States, France, Ireland and more
- Jul 27, 2021Kura Oncology's first study: phase 2 study in Squamous Cell Carcinoma of Head and NeckNew to Kura OncologyKura Oncology · NCT04997902 · 45 enrolled · United States
- Sep 1, 2021Phase 3 study in Breast NeoplasmsNovartis · NCT05038735 · 210 enrolled · Belgium, Bulgaria, Canada and more
- Dec 27, 2021Criterium's first study: phase 2 study in HER2-positive Metastatic Breast CancerNew to CriteriumCriterium · NCT05230810 · 40 enrolled · United States
- Nov 21, 2022Phase 4 study in Multiple Endocrine Neoplasia Type 1Novartis · NCT05631795 · 40 enrolled · India
- Jul 4, 2023Phase 3 study in Lymphatic AbnormalitiesNovartis · NCT05948943 · 232 planned · United States, Argentina, Australia and more
- May 21, 2025Phase 2 study in PIK3CA-related Overgrowth Spectrum (PROS)Novartis · NCT06997588 · 140 planned · United States, Australia, Austria and more
- Jun 25, 2026Phase 2 study in Breast NeoplasmsNovartis · NCT07679269 · 51 planned
- Oct 5, 2026Primary completion moved from 2028-08-02 to 2029-01-29Date moved laterphase 2 · +6 months · NCT06997588
Ahead
- Jan 28, 2027Primary completion: phase 3 study in Breast NeoplasmsNovartis · NCT05038735
- Jan 29, 2027Primary completion: phase 2 study in Breast NeoplasmsNovartis · NCT04544189
- Feb 26, 2027Primary completion: phase 2 study in Advanced Breast CancerNovartis · NCT04524000
- Feb 26, 2027Primary completion: phase 3 study in Advanced HER2+Breast CancerNovartis · NCT04208178
TargetBeta
“PI3-kinase p110-alpha subunit inhibitor”ChEMBL 37, by rule
Other programs on PIK3CA
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| inavolisibrule | Hoffmann-La Roche | phase 3 | 20 |
| tersolisib | Eli Lilly | phase 3 | 10 |
| gedatolisibrule | Pfizer | phase 3 | 9 |
| PI3K-alpha Inhibitor JS105rule | risen-suzhou-pharma-tech-co-ltd | phase 3 | 1 |
| serabelisibrule | Takeda | phase 2 | 11 |
| paxalisibrule | kazia-therapeutics-limited | phase 2 | 4 |
| risovalisibrule | Haihe Biopharma | phase 2 | 4 |
| zovegalisibrule | relay-therapeutics-inc | phase 2 | 2 |
| Mutant-selective PI3K-alpha H1047X Inhibitor SNV4818rule | pikavation-therapeutics-inc | phase 2 | 1 |
| Pan-mutant-selective PI3K-alpha Inhibitor and Degrader ETX-636rule | ensem-therapeutics | phase 2 | 1 |
| RAS/PI3K-alpha Inhibitor VVD-159642rule | Bayer | phase 1 | 1 |
| PI3Ka H1047R Mutant Selective Inhibitor CGT6297rule | cogent-biosciences-inc | phase 1 | 1 |
Studies
All 37 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07679269Breast Neoplasms | 2 | Not yet recruiting | Novartis | Mar 23, 2032 | 51 |
| NCT06997588PIK3CA-related Overgrowth Spectrum (PROS) · United States, Australia, Austria and more | 2 | Recruiting | Novartis | Jan 29, 2029 | 140 |
| NCT05948943Lymphatic Abnormalities · United States, Argentina, Australia and more | 3 | Recruiting | Novartis | May 31, 2028 | 232 |
| NCT05631795Multiple Endocrine Neoplasia Type 1 · India | 4 | Completed | Novartis | Jun 12, 2025 | 40 |
| NCT05230810HER2-positive Metastatic Breast Cancer · United States | 2 | Active, not recruiting | Criterium | Mar 30, 2026 | 40 |
| NCT05038735Breast Neoplasms · Belgium, Bulgaria, Canada and more | 3 | Active, not recruiting | Novartis | Jan 28, 2027 | 210 |
| NCT04997902Squamous Cell Carcinoma of Head and Neck · United States | 2 | Completed | Kura Oncology | Aug 29, 2025 | 45 |
| NCT04980833PIK3CA-related Overgrowth Spectrum (PROS) · United States, France, Ireland and more | 2 | Active, not recruiting | Novartis | Jun 22, 2027 | 41 |
| NCT04862143Advanced Breast Cancer · Sweden | 2 | Terminated | Novartis | Sep 19, 2022 | 2 |
| NCT04729387Ovarian Neoplasms · United States, Argentina, Australia and more | 3 | Terminated | Novartis | Apr 21, 2023 | 358 |
| NCT04589650PIK3CA-related Overgrowth Spectrum (PROS) · United States, Canada, China and more | 2 | Active, not recruiting | Novartis | Mar 20, 2024 | 236 |
| NCT04544189Breast Neoplasms · China | 2 | Active, not recruiting | Novartis | Jan 29, 2027 | 69 |
| NCT04524000Advanced Breast Cancer · Japan | 2 | Active, not recruiting | Novartis | Feb 26, 2027 | 24 |
| NCT04251533Triple Negative Breast Neoplasms · United States, Argentina, Australia and more | 3 | Terminated | Novartis | May 31, 2023 | 137 |
| NCT04208178Advanced HER2+Breast Cancer · United States, Belgium, China and more | 3 | Active, not recruiting | Novartis | Feb 26, 2027 | 19 |
| NCT03439046Breast Neoplasms · Italy | 3 | Terminated | Novartis | Dec 11, 2023 | 287 |
| NCT03056755Breast Neoplasms · United States, Argentina, Belgium and more | 2 | Completed | Novartis | Jun 14, 2021 | 383 |
| NCT02624557Hepatic Impairment · United States | 1 | Completed | Novartis | Oct 1, 2017 | 23 |
| NCT02437318Breast Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Novartis | Jun 12, 2018 | 572 |
| NCT02276027Adenocarcinoma of Lung · China | 2 | Completed | Novartis | Oct 15, 2019 | 66 |
| NCT02144038Recurrence · United States, Australia, Germany and more | 1 | Completed | Novartis | Oct 28, 2015 | 20 |
| NCT02088684Breast Neoplasms · United States, France, Italy and more | 1 | Completed | Novartis | Apr 17, 2018 | 70 |
| NCT02077933Neoplasms · United States, France, Germany and more | 1 | Completed | Novartis | Apr 12, 2019 | 79 |
| NCT02051751Neoplasms · United States, France, Italy and more | 1 | Completed | Novartis | Aug 19, 2016 | 19 |
| NCT02058381Pre-menopausal Breast Cancer · Hong Kong, Korea, Republic of, Taiwan and more | 1 | Completed | Novartis | Jun 19, 2018 | 40 |
| NCT01928459Breast Neoplasms · United States, Australia, Belgium and more | 1 | Completed | Novartis | Aug 2016 | 62 |
| NCT01923168Breast Neoplasms · United States, Australia, Austria and more | 2 | Completed | Novartis | Jul 7, 2017 | 340 |
| NCT01872260Breast Neoplasms · United States, Australia, France and more | 2 | Active, not recruiting | Novartis | Feb 26, 2027 | 259 |
| NCT01822613Esophageal Squamous Cell Carcinoma · United States, Belgium, Canada and more | 1 | Completed | Novartis | Jun 3, 2016 | 48 |
| NCT017359683rd Line GIST · United States, Belgium, France and more | 1 | Completed | Novartis | Oct 19, 2018 | 56 |
| NCT01719380Colorectal Neoplasms · United States, Australia, Belgium and more | 2 | Completed | Pfizer | Oct 31, 2015 | 156 |
| NCT01708161Breast Neoplasms · United States, Belgium, Canada and more | 2 | Terminated | Novartis | Dec 26, 2014 | 47 |
| NCT01613950Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein · United States, Germany, Japan and more | 1 | Completed | Novartis | Mar 2014 | 18 |
| NCT01602315Squamous Cell Carcinoma of Head and Neck · United States, Australia, Canada and more | 2 | Terminated | Novartis | Sep 16, 2016 | 179 |
| NCT01449058Advanced and Selected Solid Tumors · United States, Australia, France and more | 1 | Completed | Pfizer | Aug 31, 2016 | 139 |
| NCT01387321Advanced Solid Tumor · Japan | 1 | Completed | Novartis | Nov 25, 2015 | 33 |
| NCT01219699Advanced Solid Tumors With an Alteration of the PIK3CA Gene · United States, Germany, Netherlands and more | 1 | Completed | Novartis | Feb 5, 2015 | 221 |
How it is read
Names in the registry
- “Alpelisib”, 18 entries
- “BYL719”, 13 entries
- “alpelisib”, 3 entries
- “BYL719 as film-coated (FC) whole tablets”, 1 entry
- “BYL719 as dispersible tablets (DT)”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 17 studies
- Squamous Cell Carcinoma of Head and Neck, 2 studies
- Neoplasms, 2 studies
- Ovarian Neoplasms, 1 study
- Lymphatic Abnormalities, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.